Diarylpropionitrile therapy for treatment of multiple sclerosis
View Patent ↗The present invention discloses administering steroid hormones to mammals to treat autoimmune related diseases, including post-partum auto immune diseases. Most preferably the invention uses estrogens, estranges, estriol or estrogen receptor active agents to prevent or ameliorate clinical symptoms of these Th1-mediated (cell-mediated) autoimmune diseases known to either have an initial onset following the birth of a child or which are exacerbated in patients in the post-partum period.
1. A method of reducing motor impairment in a subject suffering from multiple sclerosis, comprising administering to the subject an effective amount of
2. The method of claim 1 , wherein the method treats multiple sclerosis.
3. The method of claim 1 , wherein the method reduces clinical relapses.
4. The method of claim 1 , wherein the method reduces demyelination or axonal transection.
5. The method of claim 1 , wherein the method promotes recovery of motor performance.
6. The method of claim 1 , wherein the method further comprises conjoint administration of an effective amount of a secondary agent to the subject.
7. The method of claim 6 , wherein the secondary agent is a glucocorticoid.
8. The method of claim 6 , wherein the secondary agent is prednisone or methyl prednisone.
9. The method of claim 6 , wherein the secondary agent is selected from beta-interferon, glatiramer acetate copolymer-1, azathioprine, cyclophosphamide, methotrexate, mitoxantrone and cyclosporin A.
10. The method of claim 6 , wherein the beta-interferon is interferon-beta 1a or interferon-beta 1b.
11. The method of claim 1 , wherein the subject is a human female.
12. A method of reducing motor impairment in a subject suffering from multiple sclerosis, comprising delivering to the brain of the subject an effective amount of
13. The method of claim 12 , wherein the method reduces clinical relapses.
14. The method of claim 12 , wherein the method reduces demyelination or axonal transection.
15. The method of claim 12 , wherein the method promotes recovery of motor performance.
16. The method of claim 12 , wherein the method further comprises conjoint administration of an effective amount of a secondary agent to the subject.
17. The method of claim 16 , wherein the secondary agent is a glucocorticoid.
18. The method of claim 16 , wherein the secondary agent is prednisone or methyl prednisone.
19. The method of claim 16 , wherein the secondary agent is selected from beta-interferon, glatiramer acetate copolymer-1, azathioprine, cyclophosphamide, methotrexate, mitoxantrone and cyclosporin A.
20. The method of claim 16 , wherein the beta-interferon is interferon-beta 1a or interferon-beta 1b.
21. The method of claim 12 , wherein the subject is a human female.